Bryce Point Capital LLC Invests $313,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)

Bryce Point Capital LLC acquired a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 22,709 shares of the biotechnology company’s stock, valued at approximately $313,000.

Other institutional investors have also recently bought and sold shares of the company. AlphaQuest LLC purchased a new stake in shares of Capricor Therapeutics during the 4th quarter worth about $78,000. New York State Common Retirement Fund increased its holdings in Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after buying an additional 5,000 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Capricor Therapeutics during the fourth quarter valued at approximately $91,000. Teacher Retirement System of Texas acquired a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $141,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Capricor Therapeutics in the third quarter worth approximately $161,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Trading Down 2.3 %

Shares of NASDAQ CAPR opened at $9.06 on Friday. The firm has a market capitalization of $413.82 million, a price-to-earnings ratio of -8.55 and a beta of 4.09. Capricor Therapeutics Inc has a one year low of $3.52 and a one year high of $23.40. The business has a fifty day simple moving average of $13.50 and a 200 day simple moving average of $15.02.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. On average, research analysts anticipate that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CAPR has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price target on shares of Capricor Therapeutics in a report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.